225 results on '"Raiola, A. M."'
Search Results
2. GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT
3. Thiotepa-busulfan-fludarabine Compared to Treosulfan-based Conditioning for Haploidentical Transplant With Posttransplant Cyclophosphamide in Patients With Acute Myeloid Leukemia in Remission: A Study From the Acute Leukemia Working Party of the EBMT
4. Tagraxofusp Administered Concomitantly with Intrathecal Chemotherapy in Patients with BPDCN who Either Have or are Considered High-risk to Develop CNS Disease is a Safe and Effective Treatment Strategy: An Italian Multicenter Experience
5. DLI after haploidentical BMT with post-transplant CY
6. Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update
7. Second haploidentical stem cell transplantation for primary graft failure
8. Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen
9. Mortality after bloodstream infections in allogeneic haematopoietic stem cell transplant (HSCT) recipients
10. In vivo B-cell depletion with rituximab for alternative donor hemopoietic SCT
11. Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type
12. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive allogeneic haematopoietic stem cell transplant recipients: risk factors and outcome
13. Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients
14. DISCONTINUING IMMUNOSUPPRESSIVE THERAPY FOLLOWING AN ALLOGENEIC HEMOPOIETIC STEM CELL TRANSPLANT (HSCT):A CROSS SECTIONAL ANALYSIS OF 799 PATIENTS, 1 YEAR POST TRANSPLANT: PH-P337
15. UNMANIPULATED HAPLOIDENTICAL TRANSPLANTS FOR ACUTE MYELOID LEUKEMIA (AML) AND REFRACTORY ANEMIA WITH EXCESS BLASTS (RAEB): PH-O126
16. ALLOGENEIC TRANSPLANTS FOR MYELODISPLASTIC SYNDROMES: STRONG REDUCTION OF TRANSPLANT MORTALITY IN RECENT YEARS: PH-O013
17. Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD
18. Improved outcome in young adults with de novo acute myeloid leukemia in first remission, undergoing an allogeneic bone marrow transplant
19. Allogeneic hemopoietic stem cell transplants for patients with relapsed acute leukemia: long-term outcome
20. Allogeneic Hemopoietic Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML) Prepared with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): A Retrospective Study
21. A revised day +7 predictive score for transplant-related mortality: serum cholinesterase, total protein, blood urea nitrogen, γ glutamyl transferase, donor type and cell dose
22. Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions
23. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts: a single Center experience in 488 patients: O383
24. Anti-CD26 monoclonal antibody for the treatment of steroidrefractory acute graft-versus-host disease (SR-GvHD): a report of two prospective studies: O159
25. Piperacillin/tazobactam (TazocinTM) seems to be no longer responsible for false-positive results of the galactomannan assay
26. Risk factors for non-relapse mortality in 287 patients receiving 1288 donor lymphocyte infusions: P1046
27. Unmanipulated haplo-identical bone marrow transplantation (following non-myeloablative conditioning) for advanced Hodgkinʼs lymphoma using post-transplantation cyclophosphamide: P856
28. Post-transplant CMV reactivation after CBT: the role of delayed immune reconstitution or donorʼs seronegativity?: P756
29. Myeloablative transplants from unrelated donors: intra-bone cord blood compared to adult unrelated donor; a single-centre experience: O408
30. Acute graft-versus-host disease II-IV in 1465 patients: has outcome improved over the past two decades?: O386
31. Aggressive multiple sclerosis: a single‐centre, real‐world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab
32. Risk factors for enterococcal bacteremia in allogeneic hematopoietic stem cell transplant recipients
33. Peripheral blood vs. bone marrow for molecular monitoring of BCR-ABL1 levels in chronic myelogenous leukemia, a retrospective analysis in allogeneic bone marrow recipients
34. Intrabone marrow transplantation of cord blood cells is associated with better platelet recovery and decreased acute GvHD as compared with intravenous transplantation: an EUROCORD matched-paired analysis: O106
35. Thiotepa-based reduced intensity conditioning regimen: a 10 year follow up
36. Successful non-invasive management of late-onset haemorrhagic cystitis in intrabone cord blood transplant recipients
37. Invasive aspergillosis in allogeneic stem cell transplant recipients from alternative donor: incidence, risk factors and outcome
38. Direct intra-bone injection of unrelated cord blood cells overcomes the problem of delayed/failure to engraft and improves the feasibility of haematopoietic transplant in adult patients
39. Immune reconstitution after cord blood transplantation by direct intrabone injection of cells
40. Allogeneic BMT for refractory Behçet's disease having relapsed following ABMT
41. High-dose erithropoietin in patients with persistent anaemia after allogeneic bone marrow transplantation
42. Molecular relapse of acute lymphoblastic leukaemia after allogeneic haematopoietic stem cell transplantation can be successfully treated with donor lymphocyte infusions
43. A GITMO randomised trial in steroid refractory acute graft-versus-host disease: 6methylprednisolone with or without anti-thymocyte globulin
44. Reduced intensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age
45. The combined effect of total body irradiation (TBI) and cyclosporin A (CyA) on the risk of relapse in patients with acute myeloid leukaemia undergoing allogeneic bone marrow transplantation
46. Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy
47. Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information
48. Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia after Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey
49. Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information.
50. Improved Outcome of alternative donor transplantation in patients with myelofibrosis: From unrelated to haploidentical family donors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.